Table 7.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Pancreas After Kidney (PAK) Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		29	61	55	67	113	130	157	222	303	307
Tx with Antirejection Treatments		13	27	24	25	38	41	45	59	66	43
Antibodies	Category Usage	69.2%	81.5%	66.7%	64.0%	76.3%	61.0%	57.8%	74.6%	54.5%	62.8%
	ALG	46.2%	18.5%	20.8%	16.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.0%	3.7%	4.2%	8.0%	7.9%	9.8%	8.9%	0.0%	1.5%	2.3%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.0%	5.3%	7.3%	0.0%	1.7%	0.0%	0.0%
	OKT3	46.2%	66.7%	54.2%	48.0%	68.4%	51.2%	46.7%	62.7%	34.8%	27.9%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	22.0%	22.7%	34.9%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	1.7%	1.5%	2.3%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.5%	4.7%
Corticosteroids	Category Usage	46.2%	40.7%	41.7%	48.0%	65.8%	78.0%	71.1%	84.7%	86.4%	86.0%
	Steroids	46.2%	40.7%	41.7%	48.0%	65.8%	78.0%	71.1%	84.7%	86.4%	86.0%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.